Pharmafile Logo
Pharmafocus logo
Advanced Search

Yervoy

Showing 15 posts of 56 posts found.

GSK melanoma drugs beat rival in new study

July 18, 2014
Sales and Marketing GSK, Roche, Tafinlar, Yervoy, Zelboraf, mekinist, melanoma

GlaxoSmithKline’s new combination melanoma treatment has bested Roche’s established oncology drug Zelboraf when treating patients with the deadliest form of …

News
roche_logo_shadow_7

Roche combination drug for melanoma impresses

July 14, 2014
Research and Development, Sales and Marketing GSK, Roche, Yervoy, braf, mekinist. MEK, melanoma

Roche’s investigational melanoma drug cobimetinib has helped late-stage patients live longer when used in combination with its established skin cancer …

News
BMS image

New BMS cancer treatment shines

June 25, 2014
Research and Development, Sales and Marketing ASCO, BMS, Cancer, Yervoy, braf, melanoma, nivolumab

Bristol-Myers Squibb’s investigational cancer treatment nivolumab has helped patients with the deadliest form of skin cancer to live longer. The …

News
Yervoy image

NICE recommends Yervoy

June 13, 2014
Sales and Marketing BMS, Cancer, Dillon, NHS, NICE, Yervoy, melanoma

Bristol-Myers Squibb has received a lift from the UK’s drugs watchdog, which has recommended its vaccine Yervoy as a first-line …

News
BMS image

BMS hopes for Yervoy sequel with new deal

March 18, 2014
Research and Development, Sales and Marketing Avapro, BMS, Plavix, Yervoy, five prime, immune-oncology

Bristol-Myers Squibb has announced a new research and development deal with Five Prime Therapeutics aimed at discovering potentially new cancer …

News
Amgen image

Amgen melanoma vaccine shrinks tumours

March 17, 2014
Research and Development, Sales and Marketing Amgen, Cancer, Yervoy, melanoma, t-vec

Amgen’s investigational cancer vaccine T-vec has managed to shrink the size of advanced melanoma tumours in a late-stage trial. The …

News
Yervoy image

NICE restricts Yervoy use

February 25, 2014
Sales and Marketing BMS, Cancer, NHS, NICE, Yervoy, melanoma

Bristol-Myers Squibb has been dealt a blow by NICE after the UK cost watchdog recommended that the use of skin …

News
BMS image

BMS revenue drops in 2013

January 27, 2014
Sales and Marketing AZ, BMS, Yervoy, diabetes, hep C, q4

Bristol-Myers’ Squibb’s revenue has fallen 7% year-on-year to $16.4 billion during 2013. Turnover rose 6% to $4.4 billion in the …

News
bms

Yervoy setback in prostate cancer

September 16, 2013
Research and Development, Sales and Marketing BMS, Yervoy, melanoma, prostate cancer

News
GSK image

GSK cancer vaccine fails in Phase III

September 5, 2013
Research and Development, Sales and Marketing BMS, GSK, Yervoy, melanoma, phase III

GlaxoSmithKline’s hopes of creating a cancer vaccine against the deadliest form of skin cancer took a blow today when its …

News
Tafinlar image

GSK’s skin cancer pill Tafinlar gets EMA approval

September 3, 2013
Sales and Marketing BMS, GSK, Tafinlar, Yervoy, melanoma

GSK has been granted EMA marketing authorisation for its new metastatic melanoma drug Tafinlar. The EMA’s decision on Tafinlar (dabrafenib) …

News
vaccine

Boosting immune system helps tumour fight

August 21, 2013
Research and Development, Sales and Marketing CRUK, Cancer, Iressa, Yervoy, immune system

News
Zelboraf image

Eight in ten survive skin cancer

July 22, 2013
Research and Development, Sales and Marketing Yervoy, Zelboraf, melanoma, skin cancer

The vast majority of men and women diagnosed with malignant melanoma are now surviving the disease, according to a new …

News
yervoy image

NICE hails ‘breakthrough’ skin cancer treatments

November 2, 2012
Sales and Marketing BMS, NICE, Roche, Yervoy, Zelboraf

Two new skin cancer drugs have been recommended by NICE, which hailed the drugs as ‘breakthrough treatments’. Bristol-Myers Squibb’s Yervoy …

News
yervoy image

BMS highlights Yervoy survival data

October 1, 2012
Research and Development, Sales and Marketing BMS, Roche, Yervoy, Zelboraf

Bristol-Myers Squibb’s melanoma drug Yervoy helps patients survive for longer than if they are receiving standard chemotherapy alone, according to …

News
The Gateway to Local Adoption Series

Latest content

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026

Everdrone announces new board of directors to drive expansion

February 19, 2026

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026

Indegene completes acquisition of Cake Health

February 18, 2026

Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals

February 17, 2026